11.13.20
6 min. Read

Scoop: Amwell in talks to buy Omada

Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Newsletters

Filter by
All Selling to Employers Prescription Digital Therapeutics National Virtual Clinics
    341 articles
  • First
  • Previous
    • 1 of 35
  • Next
  • Last
UnitedHealth’s employee benefits. Omada signals IPO. Detailed Spring Health pricing.
11.21.23
9 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
11.16.23
8 min. Read
Lyra Health pricing. Spring Health signals IPO.
11.09.23
6 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
11.06.23
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
10.27.23
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
10.20.23
6 min. Read
Teladoc quietly bought MSK startup. Omada hits 1M milestone.
10.13.23
5 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
10.06.23
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
9.29.23
6 min. Read
CMS: PDTs have potential. Trials: Big, Koko, GAIA
9.22.23
6 min. Read
  • First
  • Previous
    • 1 of 35
  • Next
  • Last